ZOMETA Information

ZOMETA - Prevent the event. Protect the patient.

ZOMETA is the only treatment proven to reduce the risk of bone complications across a broad range of tumor types.[1-5] ZOMETA (zoledronic acid) is a third generation bisphosphonate proven to significantly reduce or delay bone complications from multiple myeloma, or bone metastases from prostate, lung, breast and other solid tumors.[1-5] View data about the efficacy of ZOMETA.

ZOMETA is a potent inhibitor of osteolytic bone resorption and may help prevent excessive bone destruction that results in skeletal complications in metastatic bone disease.[6-8] See how ZOMETA works.

New dosing recommendations enhance renal safety for patients with reduced baseline renal function. Learn more about ZOMETA dosing and infusion. Use our convenient creatinine clearance calculator.

1. ZOMETA full prescribing information. Novartis Pharmaceuticals Corporation, 2002.
   
2. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377-387.
   
3. Kohno N, Aogi K, Minami H, et al. A randomized, double blind, palcebo-controlled, phase III trial of zoledroni acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer. Presented at the American Society of Clinical Oncology 2004 Annual Meeting (ASCO); June 5-6, 2004. Abstract 668.
   

   	Dosing & Administration Important Safety Information Mechanism of Action - ZOMETA

4. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-82.
   
5. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003; 21:3150-7.
   
6. Edelstein GA, Gillespie PJ, Grebbel FS. The radiological demonstration of osseous metastases: experimental observations. Clin Radiol. 1967;18:158.
   
7. Fogelman I, Coleman RE. The bone scan and breast cancer. In Freeman L, Weissman H (eds). Nuclear Medicine Annual. New York, NY: Raven Press;1988:1.
   
8. Boxer DI, Todd CEC, Coleman R, Fogelman I. Bone secondaries in breast cancer: the solitary metastasis. J Nucl Med. 1989;30:1318.